Wells Fargo analyst Chris Carey lowered the firm’s price target on Clorox (CLX) to $142 from $145 and keeps an Equal Weight rating on the shares. The firm says there’s a lot to consider with Q3. Boiling it all down, though, the simplest take is probably that sustained weakness in the top line combined with an ERP reversal likely erodes confidence that FY26 EPS can grow, Wells argues.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX: